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Keratoacanthoma is a rapid growing hyperkeratotic papule
occurring as a sporadic, solitary lesion on the sun-exposed
skin of elderly individuals and usually undergoes spontaneous
regression in a rapid growth over a 4-12 week period. Because
it is difficult to differentiate between keratoacanthoma and
squamous cell carcinoma in some cases, keratoacanthoma is
generally considered to be a clinically and histologically dis-
tinct entity (1, 2). However, some reports have shown that
keratoacanthoma is a type of squamous cell carcinoma with
potential for aggressiveness and metastasis (3-5).
During tumor development, a normal cell is transformed
to a malignant tumor cell via complex multi-stage processes.
Neoplastic cells have undergone numerous genetic alterna-
tions, ranging from point mutations to chromosome aberra-
tions, affecting the function or expression of both oncogenes
and tumor suppressor genes. Loss of heterozygosity (LOH) is
defined as a loss of genomic material in one of a pair of chro-
mosomes. The LOH study is designed to assess polymorphic
chromosome regions close to or within putative or known
tumor suppressor genes. Thus, the LOH analysis can be used
to obtain critical information on the discovery of new tumor
suppressor genes such as Rb, BRAC2, NF1, and NF2 (6) and
on the role of the presumptive tumor suppressor genes such
as FHIT (7) in cancer development.
In the development of sporadic colorectal cancers, mutation
of one allele of the APC tumor suppressor gene and consequent
loss of the remaining allele are among the first genetic alter-
nations (8). In the genetic progression of head and neck squa-
mous cell carcinoma, studies on premalignant lesions have
revealed LOH alternations as these premalignant lesions ad-
vance toward malignancy (9) and have indicated that LOH
can take place in an early stage of tumorigenesis.
In this study, we analyzed 10 patients with sporadic kera-
toacanthoma to assess the potential role of LOH at six loci
that previous studies displayed LOH in keratoacanthoma
(3p25, 5q22-23, 9q32, 9p21, 10q23, and 17p12) (10-12)
and at one locus known to have a specific breakpoint in a ker-
atoacanthoma (2p12-13) (13) in the development of keratoa-
canthoma.
The study group was composed of 10 patients with sporadic
keratoacanthoma (7 women, 3 men: 44-77 yr of ages, mean
63 yr). Cutaneous lesions were located on the nose (1 case),
eyelid (4 cases), cheek (4 cases), and forehead (1 case). Samples
were not collected if the lesion was recurrent, or if the patient
was an organ transplantation recipient. Also patients with a
history of prior chemotherapy or a family history of kerato-
acanthoma or visceral malignancies were not included. Unsta-
ined 5  L thick tissue sections on glass slides were deparaf-
finized twice with xylene, rinsed with 95% ethanol, and sta-
ined with hematoxylin and eosin. Selected normal or tumor
cell fields were microdissected under a light microscope using
a 30 gauge needle and transfered to 100  L of extraction
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Analysis of Loss of Heterozygosity in Korean Patients with 
Keratoacanthoma
Loss of heterozygosity (LOH) has been established as an important genetic mech-
anism giving rise to malignant neoplasia. The mechanism of LOH has been shown
to cause basal cell carcinoma and malignant melanoma as well as other types of
skin cancer. A few studies on LOH in sporadic keratoacanthomas have been report-
ed. The purpose of this study was to investigate the significance of LOH in the patho-
genesis of sporadic keratoacanthomas developed in 10 Korean patients. The pre-
sents of LOH at 7 microsatellite markers (D2S286, D3S1317, D5S346, D9S160,
D9S171, D10S185, and D17S261) were evaluated in sporadic keratoacanthomas.
LOH was found in only 1 of 10 cases at D10S185. The low frequency of LOH detect-
ed in this study suggests that LOH may not be significant in the induction of sporadic
keratoacanthomas.
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buffer (10 mM Tris-HCl, 1% Tween, 0.1 mg/mL proteinase
K, 1 mM EDTA, pH 8.0), respectively. The mixture was incu-
bated overnight at 37℃ and boiled for 10 min to inactivate
the proteinase K. The DNA solution was purified with QIA-
quick Gel Extraction Kit protocol (Qiagen, Chatsworth, CA,
U.S.A.). The purified DNA was eluted in 50  L of TE buffer
(10 mM Tris-HCl, 1 mM EDTA, pH 8.0) (14). LOH was
examined by PCR using 7 microsatellite markers as listed in
Table 1. PCR amplifications were performed with 4  L puri-
fied DNA in a reaction mixture containing 0.3  M of each
primer, 0.2 mM of each dNTP, 15 mM MgCl2, 1× reaction
buffer, and 1.25 U AmpliTaq GoldTM DNA polymerase (App-
lied Biosystems, Foster City, CA, U.S.A.) in a final volume of
30  L. PCR was performed for 35 cycles of 1 min at 94℃
for denaturing, 1 min at 55-60℃for annealing of the primers,
and 1 min at 72℃ for extension. Final extension was per-
formed at 72℃for 10 min. Five  L of each PCR product was
added to 6  L of formamide loading dye (95% formamide,
20 mM EDTA, 10 mM NaOH, 0.05% bromophenol, 0.05%
xylene cyanol) and then denatured. Four  L of the denatured
mixture was electrophoresed in 6.7% and 8% polyacryamide
gel containing 7 M urea, respectively. Silver stain was per-
formed to develop bands. Gel was fixed in 10% ethanol and
0.5% acetic acid for 6 min, then placed in 0.1% silver nitrate
for 15 min and washed twice with distilled water. Reduction
was processed in a solution containing 1.5% NaOH and 0.5%
formamide until bands developed. The gel was placed in 0.75
% Na2CO3 for 15 min, dried, and recorded. LOH was defined
as positive when a clear reduction in signal intensity was de-
tected in the tumors as compared with the corresponding nor-
mal alleles, or when a band corresponding to one allele of the
normal DNA was lost in the tumor DNA. 
The analysis of 10 sporadic keratoacanthomas matched with
normal tissue samples revealed the presence of LOH at locus
D10S185 (10q23) in only one out of the seven microsatellite
loci examined and the frequency of LOH at that locus was
found in only 1 of 10 keratoacanthomas. Fig. 1 demonstrates
the electrophoretic pattern of the LOH positive keratoacan-
thoma (case 10) along with the pattern of corresponding nor-
mal tissue. No evidence of allele shifts meaning microsatel-
lite instability was found at any of the tested markers in all
cases. 
LOH has been established as an important genetic mech-
anism giving rise to malignant neoplasia. Further more, the
mechanisms of LOH have been observed to cause benign skin
tumors. LOH loci at 9q34 and 16p13.3 in tuberous sclero-
sis harmatomas (15), at 9p22 in trichoepithelioma (16), at
16p13 in cylindroma (17), and at 1p and 9p in melanocytic
nevus (18) have been found. Cutaneous tumors such as angiofi-
broma, collagenoma, or lipoma in patients with multiple en-
docrine neoplasia type 1 and neurofibromas in neurofibroma-
tosis type 1 have been associated with allelic loss of MEN1
and NF1, respectively (19, 20). Therefore, the LOH studies
have provided a view of genetic alternations to understand
the pathogenesis of benign skin tumors.
The cytogenetic reports on keratoacanthoma are rare, but
a karyotype with complex aberrations in a keratoacanthoma
was reported in which chromosome rearrangements at both
2p13 were found (21) and we also presented a specific kary-
otype with 46,XY,t(2;8)(p13;p23) in a kearoacanthoma (13).
Thus, the 2p13 region might be important in the pathogenesis
of this skin tumor. In our study, although LOH at D2S286
(2p12-13) was not found, further other molecular studies at
2p13 in keratoacanthoma are needed to understand the bio-
logical characteristics of keratoacanthoma.
Muir-Torre syndrome is defined by the development in an
individual of at least one sebaceous gland tumor and a min-
imum of one visceral malignancy, most frequently colorectal
cancer. Additionally, further skin tumors including kerato-
acanthomas, basal cell carcinomas, squamous cell carcinomas,
and actinic keratoses have been recorded in patients suffering
from Muir-Torre syndrome (22). The APC tumor suppressor
gene on chromosome 5 was analyzed because of its common
involvement in gastrointestinal cancer (8). Our study and
other two reports in keratoacanthoma (10, 11) could not de-
tect LOH at D5S346, APC gene, suggesting that at this locus
LOH may be not important in keratoacanthoma.
Waring et al. (12) showed LOH in 11 definite keratoacan-
thoma lesions. The examined loci were known frequently to
be lost in squamous cell carcinoma of skin and in actinic ker-
atoses (3p, 9p, 13q, 17p and 17q) and on other arms chosen
at random. In that study, only two definite kearatoacanthomas
Locus 
symbol
Chromosome 
locus
Primer sequences
D2S286 2p12-13 TTAAAATTGTTTCTATGACATGATG
TGGTGGTTTATCTTACCAGTC
D3S1317 3p25 TACAAGTTCAGTGGAGAACC
CCTCCAGGCCATACACAGTCA 
D5S346 5q22-23 ACTCACTCTAGTGATAAATCGGG 
AGCAGATAAGACAGTATTACTAGTT  
D9S160 9q32 AGGAGGCTGCCATGTG
AAACCTATCTTGCCACAGAG
D9S171 9p21 AGCTAAGTGAACCTCATCTCTGTCT
ACCCTAGCACTGATGGTATAGTCT
D10S185 10q23 TCCTATGCTTTCATTTGCCA
CAAGACACACGATGTGCCAG
D17S261 17p12-11 CAGGTTCTGTCATAGGACTA
TTCTGGAAACCTACTCCTGA
Table 1. Microsatellite loci analyzed
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Fig. 1. LOH at chromosome region 10q (D10S185) in  patient No.
10. The arrow indicates the reduction of signal intensity in tumor (T)
DNA as compared with corresponding normal (N) DNA.342 T.-W. Ha, K.-H. Han, D.-G. Son, et al.
showed LOH at three loci; one showed allelic loss on chromo-
some 9p (D9S162) and 10q (D10s185), and the other showed
allelic loss on chromosome 9q (D9S160). In our study, LOH
at chromosome 10q (D10S185) was found in 1 of 10 kera-
toacanthomas and therefore our results suggest that chromo-
some 10, at least the loci we examined, does not seem to play
a major role in this tumor. And more cases of keratoacanthoma
need to be analyzed to identify that LOH on chromosome
10q at D10S185 may be related to the pathogenesis of minor
keratoacanthomas. On chromosome 3p, which region is tho-
ught to contain putative tumor suppressor genes, Waring et
al. (12) did not found LOH at D3S1293 in 9 definite kera-
toacanthomas but detected LOH in 2 of 11 patients with
probable keratoacanthomas. Peris et al. (10) observed LOH
at D3S1317 in 2 of 20 patients with keratoacanthoma; one
patient had a family history of visceral malignancies and the
other had multiple keratoacanthomas. These findings, includ-
ing our study, suggest that LOH at chromosome 3 is uncom-
mon in sporadic keratoacanthomas and may appear to be im-
portance in pathogenesis of advanced, aggressive keratoacn-
thomas or keratoacanthoma associated diseases such as Muir-
Torre syndrome.
Chromosome 17 harbors a number of tumor suppressor
genes including p53. Actinic keratoses are small, focal red
area of cutaneous dysplasia with low risk of progression to
squamous cell carcinoma. These lesions occur in sun-exposed
skin, like as keratoacanthoma. High frequencies of LOH in
actinic keratoses appeared on 17p (64%), 17q (56%), 13q
(60%), 9p (31%), 9q (44%), and 3p (26%), contrasting with
their benign clinical course (23). In keratoacanthoma, Lan-
genbach et al. (11) observed not LOH but microsatellite insta-
bility at only D17S250 (p53) in 1 of 12 sporadic keratoacan-
thomas and Peris et al. (10) detected genetic alternations at
p53 locus in 2 patients showing LOH at D3S1317 of 20 ker-
atoacanthomas. One patient with multiple kerathoacanthoma
showed LOH at 17S261 and the other patient with a family
history of visceral malignancies, putative case of Muir-Torre
syndrome, had multiple microsatellite instabilities including
those at D17S261 and D17S520. We and Waring et al. (12)
have detected no LOH at D17S261 and D17S796, respec-
tively. Borkowski et al. (24) and Perez et al. (25) demonstrated
frequency of p53 oncoprotein expression in nucleus by immu-
nohistochemical staining was high, 77% (22/26) and 94%
(15/16), respectively and suggested that p53 mutations con-
tribute to the development of this benign tumor. These find-
ings that no detection of LOH and presence of microsatellite
instability at p53 locus in definite keratoacanthomas, and high
frequency of p53 oncoprotein expression in keratoacanthomas
suggest that the genetic alternations in p53 locus are not asso-
ciated with LOH in the pathogenesis of this benign tumor.
Genetic alternations detected by LOH depend on the selec-
tion and number of chromosome markers that are chosen at
chromosome regions. The relatively low level of LOH in ker-
atoacanthoma thus may reflect the markers chosen. A com-
parative genomic hybridization study in keratoacanthoma
detected high genetic aberrations showing deletions on 3p
(20%), 9p (20%), 19p (20%), and 19q (16%) (26). Thus, more
detailed LOH study on these chromosome regions is needed
for evaluating LOH in keratoacanthoma.
In conclusion, our results suggest that LOH does not appear
to be of importance in the pathogenesis of sporadic kerato-
acanthoma and other genetic events and genes are important
in understanding the biological characteristics of keratoacan-
thoma.
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